Verastem Inc (VSTM)

1.18
NASDAQ : Health Care
Prev Close 1.18
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.05 / 2.06
Avg Volume 163.30K
Exchange NASDAQ
Shares Outstanding 36.99M
Market Cap 42.54M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Verastem Announces Presentations At ASH Annual Meeting

Verastem Announces Presentations At ASH Annual Meeting

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that new data for duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and...

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem, Inc. (NASDAQ:VSTM) and Infinity Pharmaceuticals, Inc.

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Transaction Adds Complementary Late-Stage Product Candidate from a Clinically Validated Drug Class to Verastem's Pipeline

Cancer Research UK, MSD And Verastem Collaborate To Trial New Combination Of Immunotherapy Drugs

Cancer Research UK, MSD And Verastem Collaborate To Trial New Combination Of Immunotherapy Drugs

CANCER RESEARCH UK has today (Friday) announced its first cross-company deal as part of its Experimental Cancer Medicine Centre (ECMC) Combinations Alliance.

Verastem To Present At Rodman & Renshaw 18th Annual Global Investment Conference

Verastem To Present At Rodman & Renshaw 18th Annual Global Investment Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday,...

Verastem Reports Second Quarter 2016 Financial Results

Verastem Reports Second Quarter 2016 Financial Results

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the second quarter ended June 30, 2016, and also provided an overview of certain corporate...

Verastem To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Verastem To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Wednesday, July 13th at...

Study Published In Nature Medicine Highlights Potential Role Of FAK Inhibition In Pancreatic Cancer

Study Published In Nature Medicine Highlights Potential Role Of FAK Inhibition In Pancreatic Cancer

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the publication of preclinical research in the journal Nature Medicine by the Company's researchers and scientific...

Verastem Announces Changes To Its Board Of Directors

Verastem Announces Changes To Its Board Of Directors

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced several changes to the Company's Board of Directors.

Verastem To Present At Upcoming Investor Conferences

Verastem To Present At Upcoming Investor Conferences

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming investor conferences: The Jefferies 2016...

Verastem Reports First Quarter 2016 Financial Results

Verastem Reports First Quarter 2016 Financial Results

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the first quarter ended March 31, 2016, and also provided an overview of certain corporate...

Verastem Announces The Presentation Of Clinical Data At IMig 2016

Verastem Announces The Presentation Of Clinical Data At IMig 2016

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of clinical data by Professor Raphael Bueno, M.

8 Breakout Stocks Under $10 to Trade for Big Profits

8 Breakout Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Verastem Names Gregory I. Berk, MD As Chief Medical Officer

Verastem Names Gregory I. Berk, MD As Chief Medical Officer

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the appointment of Gregory I.

Verastem Co-Founder, Dr. Robert Weinberg, Recognized With Two Prestigious Cancer Research Awards

Verastem Co-Founder, Dr. Robert Weinberg, Recognized With Two Prestigious Cancer Research Awards

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that Robert Weinberg, Ph.

Verastem Announces Presentation Of Scientific Data Supporting FAK Inhibition In Combination With Immunotherapy At The Keystone Symposium On Cancer Pathophysiology

Verastem Announces Presentation Of Scientific Data Supporting FAK Inhibition In Combination With Immunotherapy At The Keystone Symposium On Cancer Pathophysiology

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the oral presentation of preclinical data by the Company's scientific collaborator David G.

Verastem Announces Oral Presentation Of Data Supporting The Preferential Targeting Of Ovarian Cancer Stem Cells At The Society Of Gynecologic Oncology's 2016 Annual Meeting On Women's Cancer

Verastem Announces Oral Presentation Of Data Supporting The Preferential Targeting Of Ovarian Cancer Stem Cells At The Society Of Gynecologic Oncology's 2016 Annual Meeting On Women's Cancer

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of scientific data at the Society of Gynecologic Oncology's 2016 Annual Meeting on Women's Cancer...

Verastem To Present Data Supporting FAK/PYK2 Inhibition At The 2016 American Academy Of Cancer Research Annual Meeting

Verastem To Present Data Supporting FAK/PYK2 Inhibition At The 2016 American Academy Of Cancer Research Annual Meeting

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of scientific data at the 2016 American Association of Cancer Research (AACR) Annual Meeting being...

Verastem To Present Scientific Data Supporting FAK And PI3K/mTOR Inhibition To Target Cancer Stem Cells At The Keystone Symposium On Stem Cells And Cancer

Verastem To Present Scientific Data Supporting FAK And PI3K/mTOR Inhibition To Target Cancer Stem Cells At The Keystone Symposium On Stem Cells And Cancer

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of preclinical data and participation in an expert panel at the Keystone Symposium on Stem Cells...

Verastem To Present At 28th Annual ROTH Conference

Verastem To Present At 28th Annual ROTH Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will present at the 28 th Annual ROTH Conference on Tuesday, March 15 at 12:00 p.

Verastem (VSTM) Stock Spiking on Q4 Results

Verastem (VSTM) Stock Spiking on Q4 Results

Verastem (VSTM) stock is jumping after the company reported a narrower-than-expected loss for the 2015 fourth quarter.

Verastem Reports Year-End 2015 Financial Results

Verastem Reports Year-End 2015 Financial Results

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the year ended December 31, 2015, and also provided an overview of certain corporate...

7 Stocks Under $10 Making Big Breakout Moves

7 Stocks Under $10 Making Big Breakout Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Verastem To Host Conference Call On March 3rd To Discuss Fourth Quarter And Full-Year 2015 Financial Results And Recent Highlights

Verastem To Host Conference Call On March 3rd To Discuss Fourth Quarter And Full-Year 2015 Financial Results And Recent Highlights

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will host a conference call and webcast on Thursday, March 3, 2016 at 8:30 a.

Short Interest In Verastem Makes 58.3% Move

Short Interest In Verastem Makes 58.3% Move

The most recent short interest data has been released by the NASDAQ for the 01/15/2016 settlement date, which shows a 689,675 share increase in total short interest for Verastem Inc , to 1,872,660, an increase of 58.30% since 12/31/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Verastem To Present At Upcoming Investor Conferences

Verastem To Present At Upcoming Investor Conferences

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming investor conferences: 18 th Annual BIO CEO...

Verastem To Present Scientific Data Supporting FAK Inhibition In Combination With Immune Checkpoint Inhibitors At Immunotherapy World 2016

Verastem To Present Scientific Data Supporting FAK Inhibition In Combination With Immune Checkpoint Inhibitors At Immunotherapy World 2016

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of preclinical data and participation in an expert panel at Immunotherapy World 2016 being held...

Washington University In St. Louis Initiates Clinical Study Of Verastem's VS-6063 In Combination With Merck's Pembrolizumab And Gemcitabine In Pancreatic Cancer

Washington University In St. Louis Initiates Clinical Study Of Verastem's VS-6063 In Combination With Merck's Pembrolizumab And Gemcitabine In Pancreatic Cancer

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced the initiation of a Phase 1 dose-escalation study at Washington University to evaluate Verastem's FAK inhibitor...